Related Experiment Video
Updated: Mar 28, 2026
10:31
Comparative Proteomic Analysis of Whole Kidney, Medulla, and Cortical Tubules in Diabetic Pathogenesis of Kidney Injury in Mice
Published on: May 2, 2025
820
Systemic and renal lipids in kidney disease development and progression
Patricia Wahl1, Gloria Michelle Ducasa1, Alessia Fornoni2
1Peggy and Harold Katz Family Drug Discovery Center and Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, Florida.
American Journal of Physiology. Renal Physiology
|December 25, 2015
Summary
Altered lipid metabolism, not just a consequence, may cause kidney disease progression. Targeting cholesterol accumulation and enhancing high-density lipoprotein (HDL) function offers potential therapeutic strategies for kidney disease.
Area of Science:
- Nephrology
- Metabolic Research
- Cardiovascular Science
Background:
- Dyslipidemia is commonly observed in chronic kidney diseases (CKD).
- Traditionally viewed as a consequence, altered lipid metabolism is increasingly recognized as a contributor to CKD pathogenesis.
- Renal lipid accumulation is linked to various genetic and non-genetic kidney diseases.
Purpose of the Study:
- To review clinical and experimental evidence linking lipids to kidney disease pathogenesis.
- To explore the role of cholesterol accumulation and high-density lipoprotein (HDL) function in kidney disease.
- To focus on the impact of lipids on podocyte function in proteinuria and CKD.
Main Methods:
- Review of existing clinical and experimental studies.
- Analysis of data on lipid metabolism in kidney disease models.
- Examination of the role of specific lipids (cholesterol, fatty acids, sphingolipids) in renal cell function.
Main Results:
- Statins targeting cholesterol synthesis have shown limited benefit in slowing CKD progression.
- Functional high-density lipoprotein (HDL) may offer protection against cardiovascular and kidney diseases.
- Evidence suggests novel mechanisms by which lipids impact glomerular and tubular cell function.
Conclusions:
- Altered lipid metabolism is a key factor in the pathogenesis and progression of kidney disease.
- Strategies beyond statins, focusing on cholesterol efflux and HDL function, are needed.
- Further research into lipid-induced renal damage mechanisms, particularly in podocytes, is warranted.
Related Concept Videos
01:25Chronic Kidney Disease I: Introduction
1.1K
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.1K
01:24Overview of Lipid Metabolism
6.7K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
6.7K
01:24Chronic Kidney Disease II: Clinical Manifestations
945
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
945
01:28Chronic Kidney Disease III: Interprofessional Care
620
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
620
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
281
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
281
01:24Nephrotic Syndrome I : Introduction
968
Nephrotic Syndrome is a chronic kidney disorder defined by clinical findings such as severe proteinuria, hypoalbuminemia, hyperlipidemia, and edema. These symptoms result from damage to the glomeruli, the kidney’s filtering units, increasing their permeability to proteins.Definition and Meaning:Proteinuria, defined as the loss of more than 3.5 grams of protein per day in adults, is a crucial feature of nephrotic syndrome. This condition is often accompanied by edema, the accumulation of...
968